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Abstract In two crossover studies with 12 (6 males/6
females) healthy young volunteers each, we compared the
bioavailability of Neoimmun capsules with the micro-
emulsion Neoral and the influence of a fat-rich breakfast
on the bioavailability of Neoimmun. Each volunteer
received a single dose of 200 mg cyclosporine A in each
period. Blood samples were taken up to 24 h and analysed
for cyclosporine A by high-performance liquid chromatog-
raphy (HPLC) and photometric detection. The pharmaco-
kinetic parameters were determined by non-compartmental
analysis. The treatments were tested for bioequivalence and
significant differences. The bioavailability of Neoimmunwas
significantly lower compared to Neoral, albeit Neoimmun
met the bioequivalence criterion (90% confidence interval of
AUC 0.80–0.94) or missed the criterion only marginally (90%
confidence interval of cmax 0.75–0.91). The bioavailability
of Neoimmun as determined by area under the blood
concentration-time curve (AUC) increased by nearly 20%
after a fat-rich breakfast. However, mean peak concentrations
after food were only higher in male subjects, whereas mean
peak concentrations in female subjects were lower compared
to fasting administration. In conclusion, our data show that
Neoimmun exhibits a lower bioavailability than the micro-
emulsion Neoral and that food has a significant but variable
and sex-dependent impact on the bioavailability of Neo-
immun capsules.
Keywords Cyclosporine A . Food effect . Bioavailability .
Bioequivalence . Gender effect
Introduction
Cyclosporine A (CyA) is a critical dose drug with low water
solubility, and many variables have been found to influence
the bioavailability of oral CyA (Fleisher et al. 1999; Klauser
et al. 1997; Wu and Benet 2005). In contrast to the original
Sandimmune capsules, the microemulsion formulation
Neoral provides a higher and more consistent bioavailability
independent of food intake including fat-rich meals (Mueller
et al. 1994) and has set a new standard for oral CyA
medications (Ponticelli 2005). Based on bioequivalence
studies, generic formulations of CyA have been ap-
proved as bioequivalent to Neoral such as Gengraf
(Abbott, North Chicago, IL, USA), Cicloral (Hexal AG,
Holzkirchen, Germany) or Neoimmun (Kwizda Pharma,
Vienna, Austria), which is identical to Equoral (Ivax,
Miami, FL, USA). However, in two independent
crossover studies in healthy young volunteers, we found
that the bioavailability of Cicloral was significantly
lower compared to Neoral and was enhanced by more
than 25% when administered after a fat-rich breakfast.
The test of bioequivalence for Cicloral failed (Kees et al.
2004, 2006). The aim of the present study was to compare
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the bioavailability of Neoimmun with Neoral as reference
and to investigate the influence of a fat-rich breakfast on
the bioavailability of Neoimmun.
Materials and methods
Study design
The study protocol was approved by the ethics committee
of the University Hospital Regensburg. Written informed
consent was obtained from all volunteers. Volunteers were
evaluated for general good health on the basis of medical
history, physical examination, electrocardiogram and rou-
tine laboratory tests. Both studies were performed accord-
ing to an open, blockwise randomised two-period
crossover design in 12 volunteers each. There was a 1-
week washout between each treatment period of a study.
In study A, all volunteers (median, range; 6 m, age 24,
22–25 years, body weight 73, 66–75 kg, body height 180,
172–188 cm, BMI 21.4, 21.2–24.7; 6 f, age 23, 22–
30 years, body weight 58, 50–81 kg, body height 168,
158–174 cm, BMI 20.2, 19.1–26.8) received two capsules
Neoimmun (test) and two capsules Neoral (reference) with
200 ml of water on an empty stomach. In study B, the
volunteers (median, range; 6 m, age 24, 23–26 years,
body weight 71, 66–76 kg, body height 183, 175–188 cm,
BMI 21.5, 19.9–24.2; 6 f, age 24, 22–29 years, body
weight 58, 52–63 kg, body height 170, 158–172 cm, BMI
20.5, 19.4–21.3) received two capsules Neoimmun after a
fat-rich breakfast (test) and fasting (reference) with 200 ml
of water. Each capsule contained 100 mg CyA. No other
medications were permitted during the course of each
study except contraceptives. Venous blood samples for the
determination of CyA in whole blood were obtained
before drug administration (time 0) and after 0.5, 1, 1.5,
2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 h. Samples were
collected in EDTA-containing tubes and stored frozen at
−30°C. In study A, drugs were administered after an
overnight fast. Two hours later, a low-fat breakfast was
served, lunch 4.5 h, a snack 7 h, and dinner 10 h after
drug administration. In each period of study B, half of
the volunteers performed the study as in study A and
half of the subjects received the medication immediately
after a fat-rich breakfast (two eggs fried in butter, two
strips of fat bacon, 120 g hash brown potatoes, 250 ml
of whole milk and two slices of toast with butter)
according to the recommendation of the FDA (Guidance
for Industry: Food-Effect Bioavailability and Fed Bio-
equivalence Studies, Dec. 2002, http://www.fda.gov/cder/
guidance/index.htm#Biopharmaceutics). Smoking, alco-
holic and caffeine-containing beverages were not allowed
from 12 h before and up to 24 h after drug administration.
Drugs and chemicals
Neoimmun 100 mg capsules (batch no. 4T507002; expiry
date 07/2008, Kwizda) and Neoral 100 mg capsules
(Sandimmun® Optoral 100 mg capsules batch no. S0157,
expiry date 07/2008, Novartis Pharma, Nuremberg, Ger-
many) were obtained from a public pharmacy. CyA and
CyD (internal standard) were a kind gift of Novartis
Pharmaceuticals, Basel, Switzerland. Acetonitrile and meth-
anol (ultra gradient HPLC grade) were purchased from
Baker, Groß-Gerau, Germany; the other chemicals (analyt-
ical grade) from E. Merck, Darmstadt, Germany. Water was
purified by a Milli-Q water purification system (Millipore,
Eschborn, Germany).
HPLC assay
CyAwas determined by high performance liquid chromatog-
raphy (HPLC) and photometric detection at 205 nm as
published previously (Kees et al. 2006) using a mobile phase
with a slightly higher content of acetonitrile (water-
acetonitrile-methanol 350:600:60, v/v/v). CyA eluted after
6.1 and CyD after 7.1 min at a flow rate of 1.1 ml/min. The
lower limit of quantification (LLQ) was 10 ng/ml for CyA
using 1 ml of whole blood. At quality control concentrations
of CyA 1,000 (50) ng/ml, the intra-assay precision in study
A was 4.0 (3.4)%, the inter-assay precision was 0.70 (2.9)%
and the bias was −0.77 (−0.90)%. In study B, the respective
values were: intra-assay precision 3.0 or 6.8%, inter-assay
precision 2.0 or 4.7% and bias −0.60 or +0.08%.
Pharmacokinetic and statistical analysis
The pharmacokinetic parameters of CyAwere determined by
standard non-compartmental methods. Maximum blood
concentration (cmax) and time to peak concentrations (Tmax)
were directly obtained from the individual blood concentra-
tion-time curves. The elimination constant l z was calculated
by log-linear regression in the elimination phase, typically
from 8 to 24 h. The terminal half-life was calculated
according to t1/2=ln2 l
1
z . The area under the blood
concentration–time curve to the last quantifiable concentra-
tion (AUCt) was calculated by the linear trapezoidal rule.
The measured last concentration (ct) was used for extrapo-
lation to infinity to determine AUC1 ¼ AUCt þ ct λ1z . The
mean residual AUC from the last measurement point to
infinity, as a percentage of total AUC, was between 5.0%
(Neoimmun after fat-rich meal) and 5.7% (Neoimmun, study
A). The dosage regimens were tested for bioequivalence
using the statistical program BioQ PC V1.2.2 (obtained from
Dr. Steinijans, Altana Pharma, Konstanz, Germany). Ninety
percent confidence intervals were calculated according to the
two-period crossover design using the residuals from an
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appropriate analysis of variance. The range of bioequiva-
lence (AUC, cmax) was set to 80–125% using the logarith-
mically transformed data (note for Guidance on the
investigation of Bioavailability and Bioequivalence, Com-
mittee for Proprietary Medicinal Products: Commission of
the European Communities, London, 26 July 2001). The no-
difference hypothesis in Tmax was accepted if the 90%
confidence interval of the differences in Tmax included the
value “zero” (Steinijans VW 1993). In analogy to a previous
study (Kees et al. 2004), we included 12 subjects in each
study. A posterori power analysis (α=0.05) using the mean
values and the SD for the obtained differences gave a power
of 0.94 (cmax Neoral vs Neoimmun), 0.89 (AUC Neoral vs
Neoimmun) and 0.92 (AUC Neoimmun fed vs fasting),
respectively. The t test for paired data was used to compare
the difference between two treatments, and the Mann–
Whitney U test was used to evaluate differences between
male and female subjects. P values less than 0.05 were
considered statistically significant. Data are presented as
means±SD when not otherwise indicated.
Results
Tolerability
Generally, the drugs and treatments were well tolerated. Four
volunteers in study A and seven volunteers in study B
reported seven and nine episodes of burning sensations (face,
hands, feet or esophagus), respectively, shortly after drug
intake and up to 3 or 4 h. Furthermore, three episodes of
nausea were observed in study B where the drug was taken
after food. Two episodes of headache in study B and one
episode of headache, nausea and vomiting 12 hours after drug
intake in study Awere classified as non-drug-related.
Whole blood concentrations and pharmacokinetic
parameters of CyA
The mean blood concentration–time profiles of CyA are
depicted in Fig. 1. The mean blood concentrations of CyA
after Neoimmun were lower compared with Neoral
(Fig. 1a). The blood concentrations of Neoimmun increased
after a high fat breakfast and showed a slight shoulder
between 4 and 6 h (Fig. 1b). The bioavalability of Neoimmun
was 86% compared to Neoral (Table 1) and increased after a
fat-rich breakfast (Table 2). The increase in cmax after food
was less pronounced compared to the increase in AUC.
The 90% confidence interval of the ratio Neoimmun
(test) vs Neoral (reference) with respect to cmax as well as
AUC was completely below 100%. Regarding AUC, the
90% confidence intervals were at the lower limit of
bioequivalence (Neoimmun vs Neroal) or at the upper limit
of bioequivalence (Neoimmun fed vs fasting). The 90%
intervals regarding peak concentrations exceeded the range
of 80–125%. Therefore, bioequivalence could not be
demonstrated in the present study (Table 1).
Separate analysis of male and female volunteers revealed
that female volunteers showed the tendency to a lower
bioavailability. Mean peak concentrations as well as AUC
related to 70 kg body weight were lower. The difference in the
bioavailability of Neoimmun compared to Neoral was
smaller, and only AUC increased after fat-rich breakfast in
both groups (ratio fed/fasting: AUC 1.24±0.16 in male vs
1.12±0.15 in female subjects and cmax 1.40±0.28 vs 0.95±
0.31). In addition, the half-life of CyA was apparently
shorter in female subjects (Tables 1 and 2). The differences
were significant regarding peak concentrations, half-life and
AUC of Neoimmun after a fat-rich meal. Mean lower peak
concentrations after the fat-rich breakfast and a shoulder in
the blood concentrations between 4 and 6 h indicated a
biphasic absorption process in female subjects (Fig. 2b).
Discussion
Based on bioequivalence studies, generic formulations of
CyA have been approved as bioequivalent to Neoral such as
Gengraf, Cicloral or Equoral, which is identical to Neoimmun
(Ivax). However, in previous studies in 12 young healthy
volunteers, we could not demonstrate bioequivalence, neither
between Cicloral and Neoral nor between Cicloral under
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Fig. 1 Mean (SD) whole blood
concentrations of CyA in 12 (6
males/6 females) healthy young
volunteers after oral administra-
tion of two capsules Neoimmun
(closed symbols) or Neoral
(open symbols) fasting (a), and
of b Neoimmun fasting (open
symbols) or after a fat-rich
breakfast (closed symbols). Each
capsule contained 100 mg CyA
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fasting conditions and after a fat-rich breakfast (Kees et al.
2004, 2006). In particular, the bioavailability of Cicloral was
significantly lower compared to Neoral and increased by
more than 25% after a fat-rich breakfast.
In the present investigation with Neoimmun, we made
similar observations as previously with Cicloral. Under
fasting conditions, the mean bioavailability of Neoimmun
was significantly lower compared to Neoral. The 90%
confidence intervals of the ratios of AUC as well as of cmax
were totally below 100% compared to Neoral, albeit
Neoimmun met the bioequivalence criterion (AUC) or
missed the criterion only marginally (cmax). Like Cicloral
or the original Sandimmune oily suspension, the bioavail-
ability of Neoimmun increased significantly when admin-
istered after a fat-rich breakfast. However, sub-analysis of
male and female subjects revealed that in female subjects,
only AUC increased (and less than in male subjects),
whereas mean peak concentrations were even lower after
the fat-rich breakfast. The difference between male and
female subjects shows that the influence of food on the
bioavailability of Neoimmun varies, thereby impeding thera-
peutic drug monitoring using in particular peak blood con-
centrations (C2) as surrogate parameter, which is believed to
be superior to trough levels (C12; Johnston et al. 2003; Marin
et al. 2006; Morris et al. 2002; Oellerich and Armstrong 2002,
2006).
Nonetheless, our studies revealed significant differences
in the bioavailability between Neoimmun and Neoral and
between Neoimmun fasting and after a fat-rich breakfast.
The primary aim of our studies was not to demonstrate
bioequivalence, but we emphasize that we would have
probably found bioequivalence between Neoimmun and
Neoral or Neoimmun fed vs fasting using more subjects,
rendering the 90% confidence interval more narrow, as the
point estimates of cmax as well as of AUC were between 80
and 125%. Bioequivalence between Equoral (Neoimmun)
and Neoral has been reported in a previously published
study in 12 healthy volunteers according to the authors’
statement (Andrysek et al. 2003). However, the experimen-
tal setting of the study and the test medication were not
precisely described, and the result of the bioequivalence test
was not provided. Similar limitations are also applicable to
a more recent review on the bioequivalence of Neoral and
Equoral (Masri et al. 2005). However, unpublished studies
(data on file, Equoral product monograph, Ivax) have
demonstrated bioequivalence between Equoral and Neoral
Table 1 Pharmacokinetic parameters of CyA in 12 healthy young volunteers (6 males/6 females) after oral administration of two capsules
Neoimmun (test) or Neoral (reference) and test of bioequivalence (study A)
Subj. Sex BW (kg) cmax/70 kg (ng/ml) Tmax (h) t1/2 (h) AUC/70 kg
(ng/ml·h)
Nim Neo Nim Neo Nim Neo Nim Neo
1 F 60 739 923 1.5 1.5 7.1 7.2 3,725 4,175
3 F 50 845 914 2.0 1.5 6.7 6.5 5,060 5,136
7 F 56 867 1,243 1.5 1.5 3.6 2.7 3,100 3,644
8 F 60 1,066 1,207 1.0 1.5 6.2 6.2 4,251 4,552
10 F 54 802 762 1.0 1.0 6.3 6.2 2,732 2,991
11 F 81 919 1,119 1.0 1.0 3.4 3.9 2,743 3,666
2 M 73 1,350 1,457 1.5 1.5 7.7 7.2 7,673 7,767
4 M 73 872 979 1.0 1.0 8.0 7.7 3,188 3,174
5 M 75 959 942 2.0 1.5 7.3 6.7 4,989 5,011
6 M 66 875 1,247 1.5 1.0 2.9 3.4 2,739 4,096
9 M 73 1,110 1,432 1.5 1.0 6.0 5.9 4,369 5,338
12 M 72 728 1,304 1.5 1.0 6.1 6.7 3,351 4,935
Mean 66.1 928 1,127 1.42 1.25 5.93 5.85 3,993 4,541
SD 9.8 176 222 0.36 0.26 1.72 1.62 1,431 1,277
PE, 90% CI 0.83, 0.75–0.91 0.86, 0.80–0.94
P 0.005 0.003
Female subjects, n=6
Mean 60.2 873 1,028 1.33 1.33 5.54 5.45 3,602 4,027
SD 10.9 112 190 0.41 0.26 1.61 1.76 928 759
Male subjects, n=6
Mean 72.0 982 1,227 1.50 1.17 6.33 6.26 4,385 5,054
SD 3.1 219 221 0.32 0.26 1.89 1.52 1,811 1,543
P 0.298 0.066 0.576 0.337 0.472 0.230
Each capsule contained 100 mg CyA.
Nim Neoimmun, Neo Neoral, SD standard deviation, PE point estimate, CI confidence interval
396 Naunyn-Schmiedeberg’s Arch Pharmacol (2007) 375:393–399
after fasting administration evaluating data from 36
volunteers as well as after a fat-rich meal using 17 subjects.
Nonetheless, after fasting administration, the 90% confi-
dence interval was fully below 100% (AUC 90.6–98.0%,
cmax 81.0–91.6%), and after a fat-rich meal, it was fully
above 100% (AUC 100.8–108.3%, cmax 102.3–113.0%).
As the bioavailability of Neoral is not increased after a fat-
rich meal (Mueller et al. 1994), these results are in
agreement with our present findings that the bioavailability
of Neoimmun is significantly lower compared to Neoral
when administered fasting and that the bioavailability
increases significantly after a fat-rich meal.
Despite the significant differences between Equoral and
Neoral, the results met—seen separately—the current
bioequivalence criteria for approval as bioequivalent (Com-
mittee for Proprietary Medicinal Products 2002). Not
surprisingly, the validity of the current standard criteria to
establish bioequivalence between CyA formulations, based
on studies in healthy volunteers, is the subject of some
controversy (Castaneda-Hernandez et al. 1998; Cattaneo
et al. 2005; Christians et al. 2000; Johnston et al. 2004;
Meredith 2003; Qazi et al. 2006). However, pharmacoki-
netic studies in patients imply other drawbacks, such as the
need of more subjects, due to the heterogeneity of the study
Table 2 Pharmacokinetic parameters of CyA in 12 healthy young volunteers (6 males/6 females) after oral administration of two capsules
Neoimmun after a fat-rich breakfast (test) or fasting (reference), and test of bioequivalence (study B)
Subj. Sex BW (kg) cmax/70 kg (ng/ml) Tmax (h) T1/2 (h) AUC/70 kg
(ng/ml·h)
Fed Fasting Fed Fasting Fed Fasting Fed Fasting
101 F 57 804 913 1.0 1.0 5.5 6.8 3,558 3,820
103 F 58 595 575 2.0 3.0 5.7 6.1 3,649 2,921
105 F 63 700 814 1.5 2.5 5.2 6.7 3,272 3,389
107 F 56 553 660 2.0 2.0 5.6 7.1 3,847 3,255
109 F 60 1,262 840 1.0 1.5 8.1 8.3 4,171 3,215
111 F 52 588 1,027 2.5 1.5 5.1 6.2 3,759 3,500
102 M 70 1,140 879 1.0 1.0 6.0 7.5 4,661 3,717
104 M 76 1,313 881 1.0 1.5 9.1 7.7 5,079 4,436
106 M 75 1,172 1075 1.0 1.0 6.4 6.7 3,460 3,299
108 M 74 1,099 978 1.5 1.0 6.8 6.0 4,403 3,852
110 M 66 1,331 842 1.5 1.5 7.0 6.6 4,531 3,342
112 M 68 1,563 856 1.0 1.5 8.1 7.0 5,805 3,895
Mean 64.6 1,010 861 1.42 1.58 6.55 6.90 4,183 3,553
SD 8.1 306 140 0.51 0.63 1.31 0.68 748 407
PE, 90% CI 1.12, 0.94–1.34 1.17, 1.09–1.25
P 0.190 0.008
Female subjects, n=6
Mean 57.7 750 805 1.67 1.92 5.86 6.90 3,709 3,350
SD 3.7 267 165 0.61 0.74 1.14 0.80 301 302
Male subjects, n=6
Mean 71.0 1,262 911 1.17 1.25 7.24 6.90 4,629 3,732
SD 3.7 180 82 0.26 0.27 1.16 0.62 799 425
P 0.020 0.174 0.038 1.00 0.046 0.093
Each capsule contained 100 mg CyA.
NIM Neoimmun, SD standard deviation, PE point estimate, CI confidence interval
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Fig. 2 Mean (SD) whole blood
concentrations of CyA in six
male (a) or six female (b)
healthy young volunteers after
oral administration of two cap-
sules Neoimmun fasting (open
symbols) or after a fat-rich
breakfast (closed symbols). Each
capsule contained 100 mg CyA
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population or ethical problems if one group is possibly not
adequately medicated. In a 4-week, multicenter, multina-
tional pharmacokinetic study in 70 patients of different
ethnic groups (30 Asian and 40 whites), bioequivalence has
been concluded, as no significant differences were found
between the pharmacokinetics of Neoral and Equoral
(Masri et al. 2005). Nevertheless, significant differences in
a subgroup of patients could have been ignored just because
of the heterogeneity of the study population.
Based on the above-discussed issues, studies in well-
defined groups of healthy subjects are indispensable in
bioequivalence assessment procedures. However, we agree
with the conclusion in a recent review on generic
cyclosporine formulations (Cattaneo et al. 2005) “that more
restrictive criteria are required to test generic formulations
of narrow therapeutic index drugs,...as small variation in
the pharmacokinetic property of generic formulation may
result in a great impact on clinical outcome.” At least, a
retrospective analysis has revealed a significantly lower
graft survival in renal transplant recipients given a generic
CyA formulation compared with those on Neoral (cited in
Cattaneo et al. 2005).
In our small, selected population of young healthy subjects,
we observed a trend to an apparent lower bioavailability in
female compared to male subjects indicating sex-related
pharmacokinetics of CyA. The differences became more
obvious when the bioavailability parameters cmax and AUC
were normalized to 70 kg body weight. Albeit female
subjects have a higher fat content, which could influence the
tissue distribution of lipophilic drugs such as CyA, the
normalization to body weight seems to be adequate, as
studies in humans demonstrated comparable volumes of
distribution in both obese and normal-weight individuals
(Blouin and Warren 1999). Accordingly, CyA is generally
dosed on a mg/kg base.
Several studies indicate that female rats clear CyA faster
than males independently of the administration route or
dosing regimen (Molpeceres et al. 2000). A literature survey
revealed higher clearance in women than men for drugs that
are CYP3A and p-glycoprotein substrates (Christians et al.
2006). Accordingly, we observed a trend to a lower
bioavailability of CyA in female subjects during all treat-
ments and periods. The differences were significant after a
fat-rich meal, where the metabolic capacity of the body is
more challenged than after fasting administration. These
findings have not yet been confirmed in transplant patients.
Either the relevant sex-related blood levels were not
provided or the number of patients was too small. In a study
population of 19 stable renal transplant recipients (9 males/
10 females) using diltiazem as comedication to CyA (Aros
et al. 2005), a known inhibitor of oxidative CyA metabolism,
the mean increase during the comedication period was
higher in male compared to female patients (c2h 79 vs 4%,
AUC 31 vs 13%) indicating a higher capacity of women to
metabolize CyA. The differences were not significant, which
should be due to the small number of subjects and the high
variability of patients’ demographic data, but the trend is in
agreement with our results. Similarly, a study with young
Japanese pediatric patients (32 boys and 20 girls aged 5 to
27 years) revealed no gender-related differences in the
pharmacokinetics of CyA, but again, the study population
was presumably too inhomogeneous to detect gender-related
differences. However, the bioavailability increased with age
in accordance with the observation that younger patients
exhibit a higher rate of metabolism (del Mar Fernandez De
Gatta et al. 2002; Dunn 2003). In this context, we ascribe our
results rather to a higher metabolic capacity and therefore
faster clearance in female subjects than to a decreased
absorption. Furthermore, the trend to shorter half-life in
female subjects is in agreement with this assumption.
Unfortunately, we did not determine metabolites of CyA in
this study.
At least, studies in experimental animals have provided
evidence that there is a small but obvious sex-associated
difference in the survival time of the graft (Hirashawa and
Enosawa 1991; Hirashawa and Kamada 1992), with female
recipients generally rejecting organ grafts in shorter time
than males, which may be caused by sex-related differences
in the pharmacokinetics of CyA.
Conclusion
In conclusion, the bioavailability of Neoimmun is signifi-
cantly lower compared to Neoral when administered fasting
in healthy volunteers. Because food intake has a variable
impact on the bioavailability of Neoimmun, it should be
administered on a consistent schedule in relation to meals.
Future studies will have to determine whether the pharma-
cokinetic differences between Neoimmun and Neoral
reported in this study are of clinical relevance in patients
in terms of drug efficacy and side effects.
In addition, we suppose that the validity of the criteria
based on studies in healthy volunteers could be improved if
a more narrow range of bioequivalence than 80–125% were
considered for CyA and/or if CyA medications were
considered bioequivalent only if the 90% confidence
interval were not only lying within certain limits but also
included the value 100%. Those limits should be valid for
fasting administration as well as after a meal.
As female and male subjects showed unexpected differ-
ences, i.e. at least the trend for a lower bioavailability of
CyA in female subjects, we suggest that future studies in
patients should include the analysis of blood concentrations
related to sex and body weight to elucidate possible clinical
implications.
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